echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > This pharmaceutical company has a bumper harvest, and 5 new drug listing applications have been approved during the year

    This pharmaceutical company has a bumper harvest, and 5 new drug listing applications have been approved during the year

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, with the speeding up of new drug review, as well as the continuous influx of medical insurance and talents, domestic innovative drugs have developed rapidly
    .
    According to data from the China National Medical Products Administration, the sales of innovative drugs in China in 2018 were about 50 billion yuan, and it is expected to reach 171.
    1 billion yuan by 2024, with a compound annual growth rate of 22.
    76%

    .
    In this context, a number of local pharmaceutical companies have also begun to emerge and continue to harvest innovative results

    .
    On December 28, CStone Pharmaceuticals announced that the company’s gastrointestinal stromal tumor (GIST), the first precision targeted drug of its kind, AYVAKIT (avatinib), has been approved for the new drug listing application in Hong Kong, China, for the treatment of carrier Adult patients with unresectable or metastatic gastrointestinal stromal tumor with PDGFRA D842V mutation

    .
    This product is the first precise targeted drug for patients with PDGFRA D842V mutation GIST in Hong Kong, China

    .
    Data show that GIST is a sarcoma that occurs in the gastrointestinal tract, and a sarcoma is a tumor that occurs in bone or originates from connective tissue

    .
    Gastrointestinal stromal tumors originate from cells in the wall of the gastrointestinal tract and often occur in the stomach or small intestine

    .
    Most patients are diagnosed between 50 and 80 years old.
    They are usually found during gastrointestinal bleeding, surgery, or medical imaging examinations.
    They are rarely diagnosed after tumor rupture or gastrointestinal obstruction

    .
    Data show that in primary GIST, about 5% to 6% of cases are caused by the PDGFRA D842V mutation, which is a very common PDGFRA exon 18 mutation

    .
    It is understood that Avatinib was developed by Blueprint Medicines, a partner of CStone Pharmaceuticals

    .
    CStone Pharmaceuticals and Blueprint Medicines reached a relevant cooperation and licensing agreement, and obtained the development and commercialization authorization for a variety of drugs including avatinib in mainland China, Hong Kong, Macao and Taiwan.

    .
    On March 29 this year, the State Food and Drug Administration approved avatinib to be approved for marketing in China.
    Aavatinib is also China’s first approved precision treatment drug for PDGFRA exon 18 mutant GIST, which means gastrointestinal The treatment of tract stromal tumor (GIST) has entered a new era of precision treatment based on driving genes

    .
    At present, Avatinib has been successfully commercialized, and CStone Pharmaceuticals has signed strategic cooperation agreements with partners such as Sinopharm, Shanghai Meixin Health Technology, Beijing Yuanxin Technology, etc.
    , to greatly improve patients' access to drugs and payment.
    Urgent needs

    .
    Another news came on June 17 that the FDA has approved the product for the treatment of adult patients with advanced systemic mastocytosis (advanced SM), including aggressive SM (ASM) and SM with hematological tumors (SM-AHN) And mast cell leukemia (MCL), will bring more treatment options for related patients

    .
    On May 12, CStone Pharmaceuticals issued an announcement stating that the listing application of avatinib in Hong Kong has been accepted for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors with PDGFRA D842V mutation

    .
    Now, after more than 7 months, the news of approval for listing finally came, which will benefit relevant patients in Hong Kong

    .
    Up to now, CStone Pharmaceuticals has obtained approval for the marketing of 5 new drugs, namely Avatinib, Pugethua, Taijihua, Taishiwei and Zejiemei in the Greater China region, and the results have been fruitful

    .
    Among them, not long ago, the company's Shuglizumab injection (trade name: Zejiemei) was launched, which will bring new first-line treatment options for patients with advanced squamous and non-squamous non-small cell lung cancer

    .
    And this is also the first self-developed innovative product that CStone Pharmaceuticals has ushered in since its establishment

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.